僵直性脊椎炎治療市場規模、佔有率、成長分析（按治療類型、按藥物類型、按最終用戶、按地區）- 產業預測，2025 年至 2032 年

Ankylosing Spondylitis Treatment Market Size, Share, and Growth Analysis, By Treatment Type (NSAIDs, Biologics ), By Drug Type, By End-User, By Region - Industry Forecast 2025-2032

出版日期: 2025年06月11日 | 出版商:

SkyQuest | 英文 198 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球僵直性脊椎炎治療市場規模預計在 2023 年達到 31 億美元，到 2032 年將達到 60.9 億美元，預計在預測期內（2025-2032 年）的複合年成長率為 7.8%。

僵直性脊椎炎（AS）的發生率不斷上升，尤其是在年輕人和中年人中，這推動了市場擴張。 AS 是一種嚴重影響脊椎和薦髂關節的自體免疫慢性疾病，主要由 HLA-B27 基因等遺傳因素引起，在歐洲、北美和亞洲部分地區等地區很常見。隨著認知和診斷能力的提高，對透過早期診斷進行長期管理和創新治療的需求日益成長。生物療法，尤其是腫瘤壞死因子（TNF）抑制劑和白細胞介素-17（IL-17）阻斷劑，由於其能夠特異性針對發炎途徑而成為首選。正在進行的研究和開發旨在開發下一代生技藥品，加強生技藥品在治療方案中的關鍵作用並推動市場成長。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業市場定位（2024年）
主要市場參與者所採取的策略
近期市場趨勢
公司市場佔有率分析（2024年）
主要企業簡介
- 公司詳情
- 產品系列分析
- 公司分部佔有率分析
- 收益與前一年同期比較對比（2022-2024 年）
  主要企業簡介
  - 艾伯維公司（美國）
  - 諾華公司（瑞士）
  - 強生公司（美國）
  - 輝瑞公司（美國）
  - 安進公司（美國）
  - UCB SA（比利時）
  - 百時美施貴寶（美國）
  - 禮來公司（美國）
  - 羅氏控股公司（瑞士）
  - 默克公司（美國）
  - Biogen公司（美國）
  - Celgene公司（美國）
  - 武田藥品工業株式會社（日本）
  - 拜耳公司（德國）
  - 再生元製藥（美國）
  - 梯瓦製藥工業股份有限公司（以色列）
  - Sandoz International GmbH（瑞士）
  - 魯賓有限公司（印度）
  - 邁蘭公司（美國）

結論和建議

簡介目錄

Product Code: SQMIG35D2295

Global Ankylosing Spondylitis Treatment Market size was valued at USD 3.1 billion in 2023 and is poised to grow from USD 3.34 billion in 2024 to USD 6.09 billion by 2032, growing at a CAGR of 7.8% during the forecast period (2025-2032).

The rising prevalence of ankylosing spondylitis (AS), particularly among young and middle-aged adults, is significantly influencing market expansion. AS, an autoimmune chronic disorder that severely impacts the spine and sacroiliac joints, is predominantly driven by genetic factors such as the HLA-B27 gene, especially prevalent in regions like Europe, North America, and parts of Asia. As awareness and diagnostic capabilities improve, earlier diagnoses lead to an increased demand for long-term management and innovative treatments. Biologic therapies, notably tumor necrosis factor (TNF) inhibitors and interleukin-17 (IL-17) blockers, are becoming the preferred choice due to their ability to specifically target inflammation pathways. Ongoing research aims to develop next-generation biologics, reinforcing their critical role in therapeutic options and catalyzing market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Ankylosing Spondylitis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Ankylosing Spondylitis Treatment Market Segments Analysis

Global Ankylosing Spondylitis Treatment Market is segmented by Treatment Type, Drug Type, End-User and region. Based on Treatment Type, the market is segmented into NSAIDs (Non-Steroidal Anti-Inflammatory Drugs), Biologics (TNF Inhibitors, IL-17 Inhibitors), DMARDs (Disease-Modifying Anti-Rheumatic Drugs), Physical Therapy & Exercise and Others. Based on Drug Type, the market is segmented into Branded Drugs and Generic Drugs. Based on End-User, the market is segmented into Hospitals & Clinics, Specialty Clinics and Home Care. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Ankylosing Spondylitis Treatment Market

The rising global incidence of ankylosing spondylitis, especially in younger demographics, serves as a significant catalyst for the market. As more individuals receive a diagnosis, there is a growing need for effective treatment options. In response to this surge in therapeutic requirements, healthcare systems and pharmaceutical companies are dedicating increased resources to the development of innovative drugs, advanced diagnostic tools, and patient-centered care approaches. This trend highlights the urgency to meet the evolving needs of patients suffering from ankylosing spondylitis, further stimulating market growth and fostering advancements in treatment solutions.

Restraints in the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market faces significant restraints, particularly in emerging markets where a lack of general practitioner awareness and low patient knowledge lead to delayed diagnoses of this condition. Such delays can result in advanced disease progression and reduced effectiveness of treatment options. Furthermore, the shortage of skilled rheumatologists and the absence of comprehensive initial screening programs exacerbate these challenges, ultimately hindering overall market growth. Addressing these barriers is essential to enhance early detection and ensure optimal management of ankylosing spondylitis, thereby improving patient outcomes and stimulating market development.

Market Trends of the Global Ankylosing Spondylitis Treatment Market

The Global Ankylosing Spondylitis Treatment market is witnessing a significant trend towards biologics, particularly TNF and IL-17 inhibitors, which are redefining therapeutic approaches due to their targeted mechanisms and improved efficacy. This shift is propelled by robust ongoing research and development, coupled with the expansion of biosimilar options, making these advanced therapies more accessible and cost-effective. As healthcare providers and patients seek long-term disease control and enhanced quality of life, the preference for biologic treatments continues to solidify, stimulating market growth. This transition underscores the evolving landscape of ankylosing spondylitis management and underscores the importance of innovation in therapeutic regimens.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Landscape
Case Studies
Technological Analysis

Global Ankylosing Spondylitis Treatment Market Size by Treatment Type & CAGR (2025-2032)

Market Overview
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)
Biologics (TNF Inhibitors, IL-17 Inhibitors)
DMARDs (Disease-Modifying Anti-Rheumatic Drugs)
Physical Therapy & Exercise
Others

Global Ankylosing Spondylitis Treatment Market Size by Drug Type & CAGR (2025-2032)

Market Overview
Branded Drugs
Generic Drugs

Global Ankylosing Spondylitis Treatment Market Size by End-User & CAGR (2025-2032)

Market Overview
Hospitals & Clinics
Specialty Clinics
Home Care

Global Ankylosing Spondylitis Treatment Market Size & CAGR (2025-2032)

North America (Treatment Type, Drug Type, End-User)
- US
- Canada
Europe (Treatment Type, Drug Type, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Treatment Type, Drug Type, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Treatment Type, Drug Type, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Treatment Type, Drug Type, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

AbbVie Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amgen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
UCB S.A. (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Takeda Pharmaceutical Company Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Regeneron Pharmaceuticals (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sandoz International GmbH (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lupin Limited (India)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (U.S.)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments